<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3653">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352442</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-P10-020B</org_study_id>
    <nct_id>NCT01352442</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes</brief_title>
  <official_title>A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will
      provide an effective method of for the correction of presbyopia in patients who have normal
      distance vision but need correction such as glasses or contact lenses to see clearly at
      near.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design and mechanism of action of the AcuFocus™ Corneal Inlay (ACI 7000PDT) is based on
      the well-established concept of small-aperture optics. In cameras, depth of focus is
      controlled by reducing the aperture through which light enters; the smaller the aperture,
      the greater the depth of focus. This concept also applies to the human eye. In the eye of an
      emmetropic presbyope, the natural lens cannot fully accommodate to focus the light rays from
      a near object onto a single point on the retina. Thus, a point object is imaged as a blur
      circle on the retina, and images of extended objects are degraded as well. If an opaque disc
      with a small aperture in the center is placed in front of the eye, the peripheral rays will
      be obscured while the central rays pass unaffected. Since peripheral rays enter the eye at a
      larger angle, they create a larger blur circle at the retinal image plane. Eliminating these
      peripheral rays reduces the size of the blur circle, improving image resolution.

      When the inlay is implanted in one eye, the increased depth of focus provides near and
      intermediate visual acuity while having a minimal effect on distance acuity. Under binocular
      conditions, the effect of having an inlay eye with a range of vision from distance to near
      combined with the uncorrected vision in the fellow presbyopic eye, which will essentially
      have good distance acuity with reduced near acuity, is similar to the contact lens modality
      known as &quot;modified monovision.&quot;

      The ACI is expected to provide presbyopic patients with improvement in near and intermediate
      vision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Uncorrected Near Visual Acuity 20/32 or Better</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Improvement in Near Visual Acuity as Measured by Subjective Questionnaire.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcuFocus Corneal Inlay ACI 7000PDT</intervention_name>
    <description>corneal inlay</description>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <other_name>AcuFocus KAMRA inlay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must sign and be given a copy of the written Informed Consent form.

          2. Subjects must be emmetropes needing a magnitude of +1.00D to +2.50D of reading add.

          3. Subjects must have distance corrected near visual acuity worse than 20/40 and better
             than 20/100 in the eye to be implanted.

          4. Subjects must have distance visual acuity correctable to at least 20/20 in both eyes.

          5. Subjects must have a preoperative spherical equivalent of plano defined as Plano to
             -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic
             refraction in the eye to be implanted.

          6. Subjects must have a stable refraction twelve months prior to ACI implantation: i.e.
             MRSE within 0.50D over prior twelve months as determined by subject history.

          7. Subjects who are soft contact lens wearers must discontinue their contact lenses for
             at least one week prior to ACI pre-operative examination.

          8. Subjects must have a minimum central corneal thickness of ≥ 500 microns in the eye to
             be implanted.

          9. Subjects must have a corneal power of ≥ 41.00D and ≤ 47.00D in all meridians in the
             eye to be implanted.

         10. Subjects must be ≥ 45 years and ≤ 60 years of age at the time of subject eligibility
             visit.

         11. Subjects must have an endothelial cell count ≥ 2000 cells/mm2 in the eye to be
             implanted.

         12. Subjects must be willing and able to return for scheduled follow-up examinations for
             12 months after surgery.

         13. Subjects must demonstrate tolerance to monovision blur in the eye to be implanted as
             determined by loose lens blur tolerance or monovision contact lens trial.

        Exclusion Criteria:

          1. Subjects with a difference of &gt;1.00D between the spherical equivalent manifest
             refraction and the spherical equivalent cycloplegic refraction.

          2. Subjects with anterior segment pathology, including cataracts, in the eye to be
             implanted.

          3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or
             any corneal abnormality (including endothelial dystrophy, guttata, recurrent corneal
             erosion, etc.) in the eye to be implanted.

          4. Subjects with ophthalmoscopic or topographic signs of keratoconus (or keratoconus
             suspect) or keratoectasia in the eye to be implanted.

          5. Subjects with dry eye as determined by objective testing; anesthetized Schirmer's
             test result &lt;10 mm or a tear break-up time (TBUT) less than 10 seconds are excluded.

          6. Subjects taking chronic systemic medications known to exacerbate or induce moderate
             to severe dry eye in so far as measures of TBUT and Schirmers are decreased or
             borderline per Exclusion Criterion #5. Subjects taking the following classes of
             medications should be evaluated: anti-depressants, anti-histamines, beta-blockers,
             phenothiazines, atropine and atropine derivatives, oral contraceptives, anxiolytics,
             diuretics, anti-cholinergics, and anti-arrhythmics.

          7. Subjects with distorted or unclear corneal mires on topography maps of the eye to be
             implanted.

          8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology
             that would prevent an acceptable visual outcome in the eye to be implanted.

          9. Subjects who have worn RGP or PMMA contact lenses within the last 6 months.

         10. Subjects who have undergone previous intraocular or corneal surgery, including PRK,
             LASIK, CK, LASEK, and cataract surgery in the eye to be implanted.

         11. Subjects with a history of herpes zoster or herpes simplex keratitis.

         12. Subjects who have a history of steroid-responsive rise in intraocular pressure,
             preoperative IOP &gt; 21 mmHg, glaucoma, ocular hypertension, or are glaucoma suspects.

         13. Subjects with an abnormal threshold visual field.

         14. Subjects with a history of diagnosed diabetes, diagnosed autoimmune disease,
             connective tissue disease, or clinically significant atopic syndrome.

         15. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that
             may affect wound healing, and any immunocompromised subjects.

         16. Subjects who are using ophthalmic medication(s) other than artificial tears for
             treatment of any ocular pathology including ocular allergy.

         17. Subjects using systemic medications with significant ocular side effects.

         18. Subjects who are pregnant, lactating, or of child-bearing potential and not
             practicing a medically approved method of birth control.

         19. Subjects with known sensitivity to planned study concomitant medications.

         20. Subjects who are participating in any other ophthalmic drug or device clinical trial
             during the time of this clinical investigation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perry Binder, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Vision Eye Institute</name>
      <address>
        <city>Bondi Junction</city>
        <state>New South Wales</state>
        <zip>2022</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik fur Agugenheilkunde und Optometrie, Paracelsus Medzinishe Privatuniversitat Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Rothchild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinagawa Lasik Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fendalton Eye Clinic</name>
      <address>
        <city>Fendalton</city>
        <state>Christchurch</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Eye Institute</name>
      <address>
        <city>Makati City</city>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEIC Vissum Corporación Oftalmológica</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyoğlu Goz Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.acufocus.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 19, 2015</lastchanged_date>
  <firstreceived_date>May 10, 2011</firstreceived_date>
  <firstreceived_results_date>August 19, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>Accommodation</keyword>
  <keyword>Near visual acuity</keyword>
  <keyword>LASIK</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AcuFocus Corneal Inlay</title>
          <description>The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AcuFocus Corneal Inlay</title>
          <description>The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="151"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="151"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51" spread="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Japan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Singapore</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Philippines</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Turkey</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>New Zealand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Spain</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Uncorrected Near Visual Acuity 20/32 or Better</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>AcuFocus Corneal Inlay</title>
            <description>The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Uncorrected Near Visual Acuity 20/32 or Better</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="73.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Improvement in Near Visual Acuity as Measured by Subjective Questionnaire.</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AcuFocus Corneal Inlay</title>
          <description>The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Atrial Fibrilation</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for investigation of bladder. Suspected cancer. Planned event.</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Complete division of left Achilles tendon</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain and Lung cancer requiring extended hospitalization</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hospitalization for laser treatment of bladder cancer. Planned event</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pancreatic Cancer</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation for Systemic Cellulitis</sub_title>
                <description>All Serious Adverse Events reported in this study were not related to the eye.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Edema with grade of greater than or equal to 2+ (at one month or later)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Epithelial Ingrowth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Intraocular pressure</sub_title>
                <description>Intraocular pressure increase greater than 10 mmHg above baseline or Intraocular pressure greater than 25 mmHg (with clinical findings)</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Allergic reaction to study medication (lids)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>AcuFocus Corneal Inlay re-centration or replacement</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Decrease in Best Corrected Distance Visual Acuity greater than 2 lines at Month 3 or later</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Adenoviral Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Flap complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenia Thomas, OD</name_or_title>
      <organization>AcuFocus, Inc.</organization>
      <phone>949-585-9511</phone>
      <email>ethomas@acufocus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
